Cargando…
Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
BACKGROUND: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of prostaglandin E (2) and release of leukotrienes. OBJE...
Autores principales: | Rama, Tiago Azenha, Morgado, José Mário, Henriques, Ana, Escribano, Luis, Alvarez‐Twose, Iván, Sanchez‐Muñoz, Laura, Moreira, André, Romão, José, Órfão, Alberto, Matito, Almudena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967266/ https://www.ncbi.nlm.nih.gov/pubmed/35344302 http://dx.doi.org/10.1002/clt2.12132 |
Ejemplares similares
-
Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
por: González-de-Olano, David, et al.
Publicado: (2016) -
Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis
por: Dasilva-Freire, Noelia, et al.
Publicado: (2019) -
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021) -
mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
por: Rama, Tiago Azenha, et al.
Publicado: (2021) -
Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
por: Matito, Almudena, et al.
Publicado: (2013)